Chevy Chase Trust Holdings LLC Sells 1,508 Shares of Cencora, Inc. (NYSE:COR)

Chevy Chase Trust Holdings LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 1.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,728 shares of the company’s stock after selling 1,508 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Cencora were worth $20,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Concord Wealth Partners bought a new position in shares of Cencora in the 3rd quarter worth about $30,000. Kentucky Trust Co bought a new stake in Cencora during the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC increased its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Cencora during the 3rd quarter valued at about $41,000. Finally, Modus Advisors LLC bought a new stake in Cencora during the 4th quarter valued at about $54,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

COR opened at $243.03 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The company has a market cap of $46.97 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 1.49 and a beta of 0.49. The company’s 50 day moving average is $238.70 and its 200 day moving average is $237.42. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts predict that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,187 shares of company stock valued at $17,790,912. 10.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on COR shares. Wells Fargo & Company raised their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. UBS Group raised their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average target price of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.